Zepbound’s dual-action drug redefines long-term obesity and glucose control
A new weight-loss drug called Zepbound has entered the market, offering a long-term solution for managing obesity. Developed by American pharmaceutical company Eli Lilly, the treatment uses tirzepatide, an ingredient originally designed for diabetes care. Doctors say it could be more effective than earlier medications like Mounjaro (Azempic).
Zepbound works by targeting two key receptors, GLP-1 and GIP, which help regulate appetite and blood sugar. Its dual-action approach suppresses hunger, increases fullness, and slows digestion, leading to reduced calorie intake. The drug is delivered through single-use autoinjector pens for easy subcutaneous injection.
Treatment starts with a low 2.5-milligram dose to reduce side effects. Over time, the amount is gradually raised until reaching the maintenance level. Unlike short-term weight-loss aids, Zepbound is designed for extended use, often spanning months or even years. Originally developed for diabetes, the medication also improves blood sugar control. This added benefit makes it a versatile option for patients struggling with both obesity and metabolic health issues.
Zepbound represents a significant step forward in obesity treatment, combining weight management with blood sugar regulation. Its gradual dosing and long-term approach aim to provide sustainable results for patients. Eli Lilly’s latest drug is now available as an alternative to existing weight-loss medications.
